
GSK plc
GSKNYSEHealthcareDrug Manufacturers - General
Previous close
$52.41
+$0.45 · +0.87%
GSK company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
98
Deep Value
Momentum
48
Neutral
Sentiment
54
Mixed
Risk resilience
77
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteGSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Headquarters
- GB
- CEO
- Luke Victor Miels
- Listed since
- Mar 28, 1980
- Employees
- 66,841
Market position
Day range
Current $52.41
52-week range
Current $52.41
- Open
- $51.35
- Previous close
- $51.96
- Volume
- 2.23M
- 0.56× average
- Average volume
- 3.96M
- Average daily volume
- Market cap
- 105B USD
- Beta
- 0.3
- Market reference 1
- 50-day average
- $51.8666
- +1.05% above average
- 200-day average
- $52.1116
- +0.57% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 88.02B GBP
- P/E (TTM)
- 15.99×
- P/B (TTM)
- 4.36×
- P/S (TTM)
- 2.32×
- EV / EBITDA
- 8.46×
- Earnings yield
- 7.75%
- Free cash flow yield
- 7.90%
- Dividend yield
- 3.54%
Profitability & efficiency
- Gross margin
- 73.29%
- Operating margin
- 24.12%
- Net margin
- 14.52%
- Return on equity
- 34.96%
- Return on assets
- 9.37%
- Return on invested capital
- 16.61%
Financial health
- Debt / equity
- 1.03×
- Current ratio
- 0.82×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (GBP) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 32.67B GBP | 31.38B GBP | 30.33B GBP | 29.32B GBP | 24.7B GBP |
| Cost of goods sold | 9.02B GBP | 9.05B GBP | 8.57B GBP | 9.55B GBP | 8.16B GBP |
| Gross profit | 23.65B GBP | 22.33B GBP | 21.76B GBP | 19.77B GBP | 16.53B GBP |
| Research and development | 7.53B GBP | 6.4B GBP | 6.22B GBP | 5.49B GBP | 5.02B GBP |
| Selling, general, and administrative | 9.09B GBP | 11.02B GBP | 9.39B GBP | 8.37B GBP | 7.07B GBP |
| Operating expenses | 15.31B GBP | 18.31B GBP | 15.02B GBP | 13.34B GBP | 12.18B GBP |
| Interest income | 56M GBP | 67.39M GBP | 40M GBP | 64.27M GBP | 28M GBP |
| Interest expense | 687M GBP | 657.58M GBP | 775M GBP | 855.53M GBP | 784M GBP |
| Depreciation and amortization | 2.31B GBP | 2.55B GBP | 2.29B GBP | 2.15B GBP | 2.12B GBP |
| Operating income | 8.34B GBP | 4.02B GBP | 6.75B GBP | 6.43B GBP | 4.36B GBP |
| Net income | 5.72B GBP | 2.58B GBP | 4.93B GBP | 14.96B GBP | 4.39B GBP |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 100%
- 11 beats, 0 misses, 0 met estimates
- Average EPS surprise
- +12.74%
- 11 comparable reports
- Latest EPS result
- 1.36
- Estimate 1.27 · Beat by 7.09%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
29 ratingsGSK news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 22, 2022 | 4:5 | — | — |
Stock split | Nov 12, 1991 | 2:1 | — | — |
Stock split | Jan 27, 1986 | 2:1 | — | — |
Stock split | Feb 22, 1983 | 2:1 | — | — |
Stock split | Feb 13, 1980 | 2:1 | — | — |
Effective Jul 22, 2022
4:5
Effective Nov 12, 1991
2:1
Effective Jan 27, 1986
2:1
Effective Feb 22, 1983
2:1
Effective Feb 13, 1980
2:1
GSK peers
ETFs holding GSK
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Developed World ex-US ETFSPDW128.23M0.31%41.92B USD0.03%$52.02+0.79%
Avantis International Equity ETFAVDE73.04M0.39%19.1B USD0.23%$94.26+0.87%
Fidelity Enhanced International ETFFENI58.7M0.52%10.96B USD0.28%$41.72+0.77%
VanEck Pharmaceutical ETFPPH44.03M4.17%1.07B USD0.36%$116.63+1.35%
First Trust Value Line Dividend Index FundFVD33.23M0.40%8.29B USD0.62%$50.70+0.06%
GMO International Value ETFGMOI15.18M2.40%637M USD0.60%$41.625+1.35%
Hartford Multifactor Developed Markets (ex-US) ETFRODM13.97M0.85%1.65B USD0.29%$42.22+0.69%
Avantis International Large Cap Value ETFAVIV10.73M0.52%2.09B USD0.25%$83.50+0.81%
State Street SPDR Portfolio Developed World ex-US ETFSPDW- Market value
- 128.23M
- Weight
- 0.31%
- AUM
- 41.92B USD
- Expense ratio
- 0.03%
- Price / 1D
- $52.02+0.79%
Avantis International Equity ETFAVDE- Market value
- 73.04M
- Weight
- 0.39%
- AUM
- 19.1B USD
- Expense ratio
- 0.23%
- Price / 1D
- $94.26+0.87%
Fidelity Enhanced International ETFFENI- Market value
- 58.7M
- Weight
- 0.52%
- AUM
- 10.96B USD
- Expense ratio
- 0.28%
- Price / 1D
- $41.72+0.77%
VanEck Pharmaceutical ETFPPH- Market value
- 44.03M
- Weight
- 4.17%
- AUM
- 1.07B USD
- Expense ratio
- 0.36%
- Price / 1D
- $116.63+1.35%
First Trust Value Line Dividend Index FundFVD- Market value
- 33.23M
- Weight
- 0.40%
- AUM
- 8.29B USD
- Expense ratio
- 0.62%
- Price / 1D
- $50.70+0.06%
GMO International Value ETFGMOI- Market value
- 15.18M
- Weight
- 2.40%
- AUM
- 637M USD
- Expense ratio
- 0.60%
- Price / 1D
- $41.625+1.35%
Hartford Multifactor Developed Markets (ex-US) ETFRODM- Market value
- 13.97M
- Weight
- 0.85%
- AUM
- 1.65B USD
- Expense ratio
- 0.29%
- Price / 1D
- $42.22+0.69%
Avantis International Large Cap Value ETFAVIV- Market value
- 10.73M
- Weight
- 0.52%
- AUM
- 2.09B USD
- Expense ratio
- 0.25%
- Price / 1D
- $83.50+0.81%
Continue in GoAI
Research GSKresearch.disclaimer











